Core Insights - Arcutis Biotherapeutics reported strong financial performance in Q1 2025, driven by significant demand growth for its ZORYVE portfolio, which offers a safe alternative to steroids [2][6][10] - The company is expanding its market presence with additional indications and coverage for ZORYVE, alongside a promising pipeline of products [2][6][8] Financial Performance - Q1 2025 net product revenue for ZORYVE reached $63.8 million, marking a 196% increase compared to Q1 2024, but a 2% decrease from Q4 2024 [6][10] - Total revenues for Q1 2025 were $65.8 million, compared to $49.6 million in Q1 2024 [10][24] - The net loss for Q1 2025 was $25.1 million, or $0.20 per share, an improvement from a net loss of $35.4 million, or $0.32 per share, in Q1 2024 [14][24] Product Updates - ZORYVE cream and foam are approved for treating various skin conditions, with ZORYVE cream 0.3% being the most prescribed non-steroidal topical treatment for plaque psoriasis and atopic dermatitis [3][4][7] - The company has submitted supplemental New Drug Applications (sNDAs) for ZORYVE cream 0.05% for children and ZORYVE foam for scalp and body psoriasis, with action dates set for October 13, 2025, and May 22, 2025, respectively [7][10] Market Expansion - Over 425,000 prescriptions for ZORYVE cream 0.3% have been filled since its launch, indicating strong physician and patient satisfaction [7] - The company is expanding Medicaid coverage, with over 50% of recipients now covered, and all three largest national Pharmacy Benefit Managers (PBMs) covering the entire ZORYVE portfolio [2][6] Research and Development - Arcutis is advancing its pipeline, including ARQ-255 for alopecia areata, with data expected in mid-2025 [8] - The company is also developing ARQ-234, a potential biologic treatment for atopic dermatitis, with plans to submit an Investigational New Drug application in 2025 [8] Corporate Developments - Latha Vairavan was appointed as Chief Financial Officer effective May 6, 2025 [15] - The company obtained two new U.S. patents related to topical roflumilast compositions in Q1 2025 [15]

Wall Street expects a year-over-year increase in earnings on higher revenues when Arcutis Biotherapeutics, Inc. (ARQT) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 6, 2025, might help the stock move higher if these key numbers are be ...

Core Insights - The article discusses potential investment opportunities in ARQT, indicating a possible long position in the stock within the next 72 hours [1]. Group 1 - The analyst has no current stock or derivative positions in the companies mentioned but may initiate a beneficial long position [1]. - The article expresses the author's own opinions and is not influenced by compensation from any company [1]. - There is no business relationship with any company whose stock is mentioned in the article [1].

WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the pres ...

WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, Arcutis' chief financial officer (CFO) is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Mr. Topper will continue to serve as CFO ...

Arcutis Biotherapeutics, Inc. (ARQT) shares soared 10.8% in the last trading session to close at $16.60. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.8% gain over the past four weeks.The stock rallied after the company announced that Padagis had requested a stay to the ongoing patent litigation between Padagis and Arcutis. The companies agreed to stay the patent lawsuit related to Arcutis’ patented product Zoryve (roflumila ...

WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (Padagis) have requested a stay to the ongoing patent litigation between Padagis and the Company, and the Company has agreed to enter a joint stipulation to stay the case, which was filed in the ...

Group 1 - Arcutis Biotherapeutics, Inc. (ARQT) shares have increased by 25.7% over the past four weeks, closing at $16.09, with a mean price target of $20.25 indicating a potential upside of 25.9% [1] - The average price targets from analysts range from a low of $15 to a high of $29, with a standard deviation of $3.96, suggesting variability in estimates [2] - Analysts show a consensus that ARQT will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][10] Group 2 - The Zacks Consensus Estimate for ARQT has increased by 50.7% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [11] - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [12]

Core Insights - Arcutis Biotherapeutics, Inc. will participate in the 24th Annual Needham Virtual Healthcare Conference from April 7–10, 2025, with a fireside chat scheduled for April 8, 2025, at 11:00 am EDT [1] - The company focuses on developing innovations in immuno-dermatology, addressing the needs of patients with immune-mediated dermatological diseases [2] Company Overview - Arcutis is a commercial-stage medical dermatology company with a commitment to addressing persistent patient challenges in dermatology [2] - The company has a growing portfolio that includes three FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [2]

From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down ...